Structure Therapeutics
Update in progressGPCR (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company that develops and advances oral small-molecule therapies for chronic diseases with unmet needs, primarily in the United States. Its lead candidate, GSBR-1290, is a biased oral GLP-1 receptor agonist in Phase 2 for obesity and related conditions. The pipeline also includes ACCG-2671, ACCG-3535 (amylin receptor agonists in Phase 1), ANPA-0073 (APJ agonist), LTSE-2578 (LPA1 antagonist for IPF), and GIPR/GCGR programs for obesity and metabolic diseases. Formerly ShouTi Inc., founded in 2016, based in South San Francisco.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.10
- Governance
- -0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Raymond C. Stevens Ph.D.
- Founded2016
- Employees281
- Websitestructuretx.com
Identifiers
- ISINUS86366E1064
- FIGIBBG01CBVHLW1
- CIK0001888886